FDA Approves Zepbound (Tirzepatide) for Obstructive Sleep Apnea Treatment
The U.S. Food and Drug Administration (FDA) has approved Zepbound (tirzepatide) for the treatment of obstructive sleep apnea (OSA) in adults with obesity, according to official regulatory filings. This marks the first time the FDA has approved a medication specifically to treat the condition, which previously relied almost exclusively on mechanical interventions like continuous positive … Read more